Kymera IPO Presentation Deck

CANCER 1/1 FIBROSIS Liquid Tumors Solid Tumors Autoimmune Fibrosis KYMERA STAT3 Disease Impact in Oncology & Autoimmunity Genetically-defined STAT3 mutation and/or hyperactivation ALCL, T-LGL leukemia, NK/T-cell lymphoma nasal type STAT3 activation and dependency DLBCL, AML, multiple myeloma Cell Intrinsic: STAT3 role in EMT/TKI resistance Combinations in TKI/chemotherapy resistant settings Cell Extrinsic: STAT3 role in 10 T-cell infiltrated tumors. Combinations with immune-modulators STAT3 GOF syndrome Genetically-defined STAT3 mutation characterized by enteropathy, arthritis, dermatitis, lung disease Immune-inflammatory Systemic sclerosis, atopic dermatitis, rheumatoid arthritis, Crohn's disease/ulcerative colitis Chronic inflammation / fibrosis Idiopathic pulmonary fibrosis, CKD/renal fibrosis Survival, proliferation, EMT, stemness Cancer Cells STATS Cytokines (e.g., IL-6, IL-10, VEGF) STATS Myeloid Cells (Macrophages, MDSCS) Tregs Immature DCs PD-L1 STATS Endothelial Cells Vascularization

View entire presentation